Holen Sie sich die Stockscreener-App
1.38
0.00%
0.00
Handel nachbörslich:
1.37
-0.010
-0.72%
Schlusskurs vom Vortag:
$1.38
Offen:
$1.38
24-Stunden-Volumen:
4.81M
Relative Volume:
5.27
Marktkapitalisierung:
$56.51M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-66.88M
KGV:
-0.8364
EPS:
-1.65
Netto-Cashflow:
$-62.91M
1W Leistung:
+0.00%
1M Leistung:
+23.21%
6M Leistung:
+94.60%
1J Leistung:
+1.47%
1-Tages-Spanne:
$1.3601
$1.39
1-Wochen-Bereich:
$1.36
$1.39
52-Wochen-Spanne:
$0.63
$1.52
Achilles Therapeutics Plc Adr Stock (ACHL) Company Profile
Firmenname
Achilles Therapeutics Plc Adr
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie ACHL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACHL
Achilles Therapeutics Plc Adr
|
1.38 | 56.51M | 0 | -66.88M | -62.91M | -1.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Achilles Therapeutics Plc Adr Stock (ACHL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-04-05 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-04-26 | Eingeleitet | BofA Securities | Buy |
| 2021-04-26 | Eingeleitet | Chardan Capital Markets | Buy |
| 2021-04-26 | Eingeleitet | JP Morgan | Underweight |
| 2021-04-26 | Eingeleitet | Oppenheimer | Outperform |
| 2021-04-26 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Achilles Therapeutics Plc Adr Aktie (ACHL) Neueste Nachrichten
Achilles Therapeutics plans to leave Nasdaq and liquidate - Investing.com
Achilles Therapeutics Announces Voluntary Nasdaq Delisting and SEC Deregistration - GlobeNewswire Inc.
Check Out Achilles Therapeutics Plc ADR (ACHL)’s Trade Data Rather Than the Analysts’ Views - SETE News
Hut 8 Corp (HUT) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
A History of Outperforming Analyst Forecasts and Beating the Odds: Sprinklr Inc (CXM) - SETE News
An Analysis of NovoCure Ltd (NVCR)’s Potential Price Growth - Knox Daily
The Attractiveness of Investing In Enerflex Ltd (EFXT) is Growing - Knox Daily
Taking a Closer Look At VNET Group Inc ADR (VNET) Following Its Recent Trade - Knox Daily
A Guide To The Risks Of Investing In Achilles Therapeutics Plc ADR (ACHL) - Knox Daily
Its Stock Has Paid Off Big Time For ASE Technology Holding Co.Ltd ADR - SETE News
Sacks Parente Golf Inc (SPGC) Shares Decline Despite Market Challenges - The News Heater
Take off with Fate Therapeutics Inc (FATE): Get ready for trading - SETE News
Top investors say Lam Research Corp (LRCX) ticks everything they need - SETE News
It is Poised to be a Bull Market for Allot Ltd (ALLT) - SETE News
Stocks of Achilles Therapeutics Plc ADR (ACHL) are poised to climb above their peers - SETE News
Piper Sandler gives a Neutral recommendation for Achilles Therapeutics Plc ADR (ACHL) - Knox Daily
Do you want to know where to find good stock? Take a look at Achilles Therapeutics Plc ADR’s (NASDAQ:ACHL) Sentiment Analysis – US Post News - US Post News
JMP Securities downgrades PJT Partners Inc (PJT) rating to a Mkt perform - Knox Daily
Hexcel Corp (HXL) receives an Outperform rating from RBC Capital Mkts - Knox Daily
Lloyds Banking Group plc ADR (LYG) rating downgrades by Morgan Stanley - Knox Daily
Did Caredx Inc (CDNA) perform well in the last session? - US Post News
Examining Immatics N.V (IMTX) more closely is necessary - US Post News
Achilles Therapeutics Plc ADR Inc. (ACHL) Price Performance: A Technical Analysis Perspective - The InvestChronicle
TPX’s 2023 Market Dance: Up 18.05% – Time to Invest? - The InvestChronicle
Rezolve AI Ltd: A Year of Highs, Lows, and Market Resilience - The InvestChronicle
Head to Head Review: OPHIR ENERGY PL/ADR (OTCMKTS:OPHRY) vs. HOYA (OTCMKTS:HOCPY) - Defense World
80+ Pharma Companies Unite to Shape the Future of RNA-Based Therapeutics | DelveInsight - 新浪香港
ACHL’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Is Achilles Therapeutics (ACHL) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
why Achilles Therapeutics Plc ADR [ACHL] is a Good Choice for Investors After New Price Target of $1.25 - The DBT News
What Analysts Were Expecting After PowerFleet Inc (NASDAQ: AIOT) rose 2.40% - Stocks Register
Achilles Thera shifts focus to new cancer treatment avenues - The Pharma Letter
Achilles Therapeutics ends TIL-based cancer therapy trials - Investing.com
You Should Read This Analysis Before Investing in Achilles Therapeutics Plc ADR (NASDAQ:ACHL) - US Post News
Achilles stock climbs on strategic focus (NASDAQ:ACHL) - Seeking Alpha
Achilles Therapeutics Announces Strategic Update - Yahoo Finance
Achilles Therapeutics Announces Research Collaboration with - GlobeNewswire
Achilles Therapeutics faces Nasdaq delisting over share price - Investing.com
Is Acadia Healthcare (ACHC) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights - GlobeNewswire
10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis - Yahoo Finance
What Makes Achilles Therapeutics PLC Sponsored ADR (ACHL) a New Buy Stock - Yahoo Finance
Apellis' (APLS) Empaveli Aids Growth, Stiff Competition a Woe - Yahoo Finance
IVERIC bio (ISEE) Posts Positive Top-Line Data From GA Study - Yahoo Finance
Immuneering (IMRX) Files IND for Cancer Candidate IMM-1-104 - Yahoo Finance
Novo (NVO) Posts Positive Data From Diabetes Study on CagriSema - Nasdaq
ICE Announces Annual Reconstitution Changes in the ICE Biotechnology Index - Business Wire
Achilles Therapeutics Raises £52.7 Million in an - GlobeNewswire
ADVFNFree stock and cryptocurrency prices, charts, market news and streaming real-time quotes. - ADVFN
Finanzdaten der Achilles Therapeutics Plc Adr-Aktie (ACHL)
Umsatz
Nettogewinn
Free Cashflow
ENV
6.45%
1.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):